Medically reviewed by Nicholas R. Metrus, MD Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) are both diseases that affect your central nervous system ...

Increased consumer and medical professional knowledge regarding novel treatments is predicted to drive growth in the global amyotrophic lateral sclerosis (ALS) treatment market. The introduction ...

SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

The Food and Drug Administration (FDA) has granted accelerated approval to Qalsody ™ (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) who have a mutation in the ...

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | ...

July 7, 2022 Degradation of motor neurons, conceptual computer illustration. Amyotrophic lateral sclerosis, also referred to as Lou Gehrig's disease is the most common of the motor neuron diseases.

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Focused on Advancing NurOwn into Phase 3b ENDURANCE Trial BrainStorm ...